Global Regulatory and Scientific Policy, The Healthcare Business of Merck KGaA, Darmstadt, Germany. *Corresponding Author: Marén U. Koban, Global Regulatory Affairs, The Healthcare Business of Merck ...

Search for other works by this author on: ...

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

Search for other works by this author on: ...

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.

University of Nebraska Medical Center, Omaha, NE, ...

According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...